Regeneron Pharmaceuticals


Check Out All the Stocks I'm Buying and Shorting This Week

So, here we are: The first Fed rate cut in 10 years is in the history books, and the markets have completely changed… right?

Nope. The markets instead took everyone for a roller coaster ride down – selling the news.

But there are still a TON of opportunities out there worth your hard-earned capital, and I'm going to show you the best moves to make when the markets open tomorrow.

We just have to re-focus our attention on the earnings calendar - it's the key to making money this week...


Get Your Hands on the World's First $1 Billion Cannabis Drug

When it comes to biotech, Wall Street tends to overreact. Though there's no reason for it to be there, biotech is in the dog house, and investors have been conditioned to punish the sector and its stocks whenever the opportunity presents itself.

You see, there are three main reasons biotech is down: Wall Street is worried about high and rising drug prices, the impact of a possible trade war on foreign sales, and expiring patents for some older medications.

Over the last several years, for example, I've read a number of Wall Street reports about the so-called "biotech patent cliff." Simply stated, a drug falls off that "cliff" when its patent runs out and it starts facing competition from generics.

And a number of successful drugs out there are rapidly approaching their patent cliffs.

That sounds bad.

But there are good things happening in biotech, as well. In fact, what you don't hear much about is that the industry is about to bust out.

For example, I was thrilled to see a recent report from Clarivant Analytics, a research firm that works closely with industry leaders and top universities, which says a total of 12 compounds being released in 2018 could become blockbusters.

So I went through the data and found one ultimate biotech blockbuster that I think could lead the pack.

Let's take a look...

Dow Jones

Why the Dow Jones Today Is Flat After Last Night's Elections

The Dow Jones today is flat in pre-markets hours after Democrats were swept to victory in Virginia and New Jersey during statewide elections last night.

Dow Jones futures are down nine points as traders are now uncertain over what the elections will mean for Congress, especially as the House gears up for their election in 2018.

Here's a look at today's most important market events and stocks, plus a look at today's economic calendar...


If You Own Just One Pharma Stock, Make It This

As I've said before, buying a drugmaker with true billion-dollar "blockbuster" potential is like grabbing a license to print money.

Of course, it's always at least possible to grab these shares on their way up, but that's a little like fixing the barn door after the horses have bolted.

For the biggest possible pharma profits, investors have to look ahead into the firm's "pipeline," its arsenal of yet-to-be-released drugs that's critical to keeping a drug company competitive in the long term.

Today, I've got the perfect "Buy" recommendation for a company that's doing just that...